triple agonist glp 1 Beyond GLP-1: Retatrutide's triple-agonist mechanism (GLP-1, GIP, glucagon) is redefining metabolic health. Phase 2 data shows ~24% weight loss—surpassing semaglutide & tirzepatide. Evidence-based protocols demand nutrition support alongside prescribing Retatrutide: How the Triple Agonist
Description
Expanded FDA Indications In 2024/2025 The potential uses for GLP-1s are expanding rapidly, moving well beyond their original purpose of diabetes management
doi: 10.1093/eurheartj/ehad192
If this is the case, she adds that its extremely important to be in contact with the patients therapist and/or psychiatrist
There are no clinical trials demonstrating weight loss from this specific product
